Giles Platford/LinkedIn
Dec 12, 2025, 09:34
Giles Platford on Baby Big: Plasma-Derived Drug Against Infant Botulism
Giles Platford, President, Plasma-Derived Therapies Business Unit at Takeda and Chair of the Global Executive Board at PPTA, shared on LinkedIn:
”Plasma-derived therapies are often the only effective treatment for patients with certain rare and complex, chronic conditions.
One case in point is infant botulism: in partnership with the California Department of Public Health, on a non-profit basis, Takeda produces the only FDA-approved treatment for this condition, Baby Big.
The recent outbreak of infant botulism in the U.S. has put a fine point on the importance of this therapy.
Learn more in this story from The Independent”
Stay updated with Hemostasis Today.
-
May 1, 2026, 17:55Salih Ehsan: The Deceptive Nature of B12 Deficiency Not Just Anemia
-
May 1, 2026, 17:45Angela Blue: Insurance Education as a Tool for Strengthening Patient Communities
-
May 1, 2026, 17:36Smitirupa Mishra: Hematology Formulas Made Simple, Structured, And Useful For Everyday Clinical Practice
-
May 1, 2026, 17:00Frank Weinz: VTE Prevention Strategies and Advances in Clinical Practice
-
May 1, 2026, 16:54Pierre François Sabouret: Women’s Health Should Be a Priority for All HCPs, Not Just WIC
-
May 1, 2026, 16:44Jean Jacques Kiladjian: A Global Triumph in MPN Research at ESHMPN 2026
-
May 1, 2026, 16:36Shek Sady Khan: VTE as a Major Yet Underrecognized Cause of Preventable Morbidity and Mortality
-
May 1, 2026, 16:11Anu Thomas: History of Blood Transfusion
-
May 1, 2026, 16:01A 100-Study Systematic Review Reevaluates PT and aPTT Testing in Perioperative Bleeding – JTH